Artificial Intelligence Biotech China Guangdong Healthcare Hong Kong Investment Shanghai Shenzhen stock exchange
Ascletis Pharma Inc. has been included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs. This inclusion allows eligible investors in mainland China to trade Ascletis’ shares through the Hong Kong Stock Connect channel. The company sees this as market recognition of its investment value and growth prospects, expecting it to expand its shareholder base and increase trading liquidity. Ascletis believes this move will support its long-term innovation-driven growth. The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are mechanisms that enable investors in mainland China and Hong Kong…
News Timeline:
Track the development of this news story across the Internet.